Your browser is no longer supported. Please, upgrade your browser.
Vincerx Pharma, Inc.
Index- P/E- EPS (ttm)-3.62 Insider Own22.10% Shs Outstand17.86M Perf Week-7.97%
Market Cap280.40M Forward P/E- EPS next Y-2.76 Insider Trans0.62% Shs Float11.92M Perf Month31.16%
Income-22.90M PEG- EPS next Q-0.77 Inst Own75.00% Short Float9.70% Perf Quarter29.22%
Sales- P/S- EPS this Y-30.40% Inst Trans32.30% Short Ratio6.79 Perf Half Y-34.67%
Book/sh- P/B- EPS next Y-3.80% ROA- Target Price29.67 Perf Year55.29%
Cash/sh4.79 P/C3.28 EPS next 5Y- ROE- 52W Range10.00 - 26.75 Perf YTD-24.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.31% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low57.00% ATR1.15
Employees28 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)52.99 Volatility8.17% 8.04%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume6.23 Prev Close15.94
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume170.23K Price15.70
Recom2.00 SMA200.79% SMA508.91% SMA200-6.31% Volume1,059,927 Change-1.51%
Sep-13-21Initiated Laidlaw Buy $30
Aug-25-21Initiated B. Riley Securities Buy $26
Sep-16-21 07:30AM  
Sep-07-21 08:00AM  
Aug-12-21 04:05PM  
Jul-30-21 09:55AM  
Jul-01-21 02:42AM  
Jun-28-21 08:00AM  
Jun-04-21 12:40PM  
Jun-03-21 04:05PM  
May-26-21 08:00AM  
May-17-21 08:00AM  
May-06-21 08:00AM  
Apr-20-21 08:00AM  
Apr-10-21 08:31AM  
Apr-07-21 08:00AM  
Apr-05-21 08:00AM  
Apr-01-21 08:00AM  
Mar-30-21 09:24AM  
Mar-23-21 08:00AM  
Mar-10-21 04:32PM  
Mar-02-21 08:00AM  
Feb-24-21 08:00AM  
Feb-17-21 08:00AM  
Jan-07-21 04:01PM  
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Izumi Raquel E.See RemarksAug 04Buy11.961,00011,9601,000Aug 06 04:45 PM
Hwang SooinChief Business OfficerJun 30Buy12.665006,330385,575Jun 30 06:56 PM
Lee John H.DirectorJun 29Buy12.7179910,159799Jul 01 06:52 PM
McDonald Andrew IDirectorJun 29Buy12.3820,000247,60020,000Jul 01 06:05 AM
THOMAS TOM CSee RemarksJun 29Buy12.582,00025,1602,000Jun 30 06:57 PM